Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
CCCA Disease Activity Scale and Treatment Strategies
Description
The speaker explains a practical approach to central centrifugal cicatricial alopecia (CCCA), emphasizing that it is the most common scarring alopecia in Black women and is increasingly linked to insulin resistance and metabolic disease. Because regrowth is hard to measure and patients can feel discouraged, the speaker developed a CCCA disease activity scale to track whether treatment is working and to help patients see value in follow-up care. The scale is based on disease progression, pain, pruritus, scalp resistance/fibrosis, and erythema, with the goal of reducing all scores to zero rather than simply counting severity upward. Treatment is framed as needing both anti-inflammatory and anti-fibrotic effects: standard first-line therapies include topical steroids, intralesional steroid injections, and tetracyclines, with metformin highlighted as especially useful when metabolic disease, insulin resistance, or scalp fibrosis is present. Oral metformin is supported by RNA sequencing data showing reversal of fibrotic pathways and decreased inflammation, and some patients had hair regrowth, particularly younger patients with parietal involvement. For scalp pain, doxycycline is often added; for persistent itch, especially when inflammation treatments fail, neurogenic itch may respond to compounded amitriptyline, lidocaine, ketamine, and menthol. Trichoscopy is recommended to detect subtle erythema and perifollicular changes. In the speaker’s retrospective data, most patients improved on standard therapy, with 88% improving after six months and 48% reaching remission, and quantified improvement helped patients stay engaged and allowed spacing visits out once they remained stable.
View moreConclusions
- CCCA appears to be driven by both inflammation and fibrosis, so effective treatment needs to address both processes rather than inflammation alone.
- A symptom-guided disease activity scale can help quantify CCCA severity, monitor response over time, and give patients clearer evidence that treatment is working.
- Intralesional steroids and high-potency topical steroids remain core therapies, and doxycycline is useful when pain, tenderness, or inflammatory signs are present.
- Metformin shows particular promise in CCCA because it may reverse profibrotic pathways while also reducing inflammation, with some patients showing hair regrowth.
- Patients with evidence of insulin resistance or metabolic disease may be especially good candidates for oral metformin, while topical metformin may be useful in selected cases.
- Scalp pain, pruritus, erythema, and injection resistance each provide different clues to disease activity and can guide add-on therapy choices.
- When itch persists despite anti-inflammatory treatment, a neurogenic component may be present and nerve-targeting compounded therapies may help.
- Trichoscopy is important because erythema in CCCA is often subtle and may only be visible under magnification.
- Most patients improved with standard therapies in the retrospective study, and nearly half reached remission after six months.
- Quantifying disease activity helps both clinicians and patients by making improvement visible, supporting adherence, and allowing treatment to be spaced out once stable remission is achieved.
- Qadri A, Will E, Aguh C. Using disease symptomatology to guide treatment in patients with central centrifugal cicatricial alopecia: introduction of C-CAT scoring tool. Skin Appendage Disorders. 2025.#10.1159/000544777
- Bao A, et al. Low-dose metformin and profibrotic signature in central centrifugal cicatricial alopecia. JAMA Dermatology. 2024.#10.1001/jamadermatol.2024.3062
- O'Donoghue and Tharp. 2005.
- Gadre et al. 2023.